Literature DB >> 21655925

Watchful waiting and active surveillance approach in patients with low risk localized prostatic cancer: an experience of out-patients clinic with 12-year follow-up.

Sergey Kravchick1, Ronit Peled, Shmuel Cytron.   

Abstract

In this study we evaluated the safety of expectant approach in the patients with low risk prostate cancer in the reality of community based out-patients clinics. 48 men were enrolled into the study. The inclusion criteria were age ranged from 60 to 75 years and the Epstein criteria for low risk prostate cancer. Patients were managed expectantly while curative treatment was offered when indicated. Initial and final Charlson comorbidity index (CCI) and BMI were assessed for all men. Patients' median follow-up was 81.1 ± 29.1 years. During this study 41.7% of the patients chose active forms of treatment. Cancer was found in 20.8% (n-10) of our patients. Two first sessions of re-biopsy diagnosed 92% of T1c upgrading. Six men with CCI ≥2 died from concomitant disease and no one died from PCa. Significant correlation was found between BMI and final CCI ≥2 (p-0.001). Expectant approach can be considered as self alternative to active treatment model in selected group of patients with well differentiated PCa, however 20.8% of these patients are still at risk of having aggressive form of cancer. Expectant approach is particular beneficial for the patients with CCI 1-2 and high BMI.

Entities:  

Mesh:

Year:  2011        PMID: 21655925     DOI: 10.1007/s12253-011-9400-0

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  19 in total

1.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 2.  Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study.

Authors:  B Djavan; M Waldert; A Zlotta; P Dobronski; C Seitz; M Remzi; A Borkowski; C Schulman; M Marberger
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

3.  Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.

Authors:  Stijn Roemeling; Monique J Roobol; Renske Postma; Claartje Gosselaar; Theo H van der Kwast; Chris H Bangma; Fritz H Schröder
Journal:  Eur Urol       Date:  2006-05-03       Impact factor: 20.096

4.  Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.

Authors:  E W Steyerberg; M J Roobol; M W Kattan; T H van der Kwast; H J de Koning; F H Schröder
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

5.  Comorbidity in patients with prostate cancer and its relevance to treatment choice.

Authors:  P N Post; P J Kil; A J Hendrikx; M L Janssen-Heijnen; M A Crommelin; J W Coebergh
Journal:  BJU Int       Date:  1999-10       Impact factor: 5.588

6.  Saturation prostate biopsy in high risk patients after multiple previous negative biopsies.

Authors:  Kobi Stav; Dan Leibovici; Judith Sandbank; Arie Lindner; Amnon Zisman
Journal:  Urology       Date:  2008-03       Impact factor: 2.649

7.  What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.

Authors:  Daniel A Barocas; Janet E Cowan; Joseph A Smith; Peter R Carroll
Journal:  J Urol       Date:  2008-08-15       Impact factor: 7.450

8.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

9.  Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis.

Authors:  Patrick J Bastian; Leslie A Mangold; Jonathan I Epstein; Alan W Partin
Journal:  Cancer       Date:  2004-11-01       Impact factor: 6.860

10.  Validation of the contemporary epstein criteria for insignificant prostate cancer in European men.

Authors:  Claudio Jeldres; Nazareno Suardi; Jochen Walz; Georg C Hutterer; Sascha Ahyai; Jean-Baptiste Lattouf; Alexander Haese; Markus Graefen; Andreas Erbersdobler; Hans Heinzer; Hartwig Huland; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2007-12-07       Impact factor: 20.096

View more
  1 in total

1.  Active surveillance for the management of localized prostate cancer: Guideline recommendations.

Authors:  Chris Morash; Rovena Tey; Chika Agbassi; Laurence Klotz; Tom McGowan; John Srigley; Andrew Evans
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.